Workflow
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
ACRSAclaris Therapeutics(ACRS) GlobeNewswire·2025-02-27 11:59

Core Insights - Aclaris Therapeutics is positioned for multiple clinical catalysts in 2025, particularly with Phase 2 data for bosakitug in severe asthma and chronic rhinosinusitis with nasal polyps expected in the first half of 2025 [1][3] - The company has a strong cash runway expected to last into 2028, bolstered by a recent 80millionprivateplacement[5][7]PipelineDevelopments−AclarishasannouncedanexclusivegloballicenseagreementwithBiosion,acquiringrightstobosakitug(ATI−045)andATI−052,whicharepotentialbest−in−classbiologicassets[4]−Phase2studiesforbosakituginChinesepatientswithsevereasthmaandchronicrhinosinusitisareongoing,withdataexpectedinthefirsthalfof2025[4][3]−APhase2btrialforbosakituginatopicdermatitisissettobeginenrollmentinthefirsthalfof2025[1][4]−Top−lineresultsfromaPhase2atrialofATI−2138inatopicdermatitisarealsoanticipatedinthefirsthalfof2025[3][4]FinancialPerformance−ForQ42024,Aclarisreportedanetlossof80 million private placement [5][7] Pipeline Developments - Aclaris has announced an exclusive global license agreement with Biosion, acquiring rights to bosakitug (ATI-045) and ATI-052, which are potential best-in-class biologic assets [4] - Phase 2 studies for bosakitug in Chinese patients with severe asthma and chronic rhinosinusitis are ongoing, with data expected in the first half of 2025 [4][3] - A Phase 2b trial for bosakitug in atopic dermatitis is set to begin enrollment in the first half of 2025 [1][4] - Top-line results from a Phase 2a trial of ATI-2138 in atopic dermatitis are also anticipated in the first half of 2025 [3][4] Financial Performance - For Q4 2024, Aclaris reported a net loss of 96.6 million, compared to a net loss of 1.5millioninQ42023[8]−TotalrevenueforQ42024was1.5 million in Q4 2023 [8] - Total revenue for Q4 2024 was 9.2 million, down from 17.6millioninQ42023,primarilyduetoaone−timepaymentreceivedinthepreviousyear[9]−Researchanddevelopmentexpensesdecreasedto17.6 million in Q4 2023, primarily due to a one-time payment received in the previous year [9] - Research and development expenses decreased to 9.0 million in Q4 2024 from 26.6millionintheprioryear[10]−Generalandadministrativeexpensesalsosawareduction,totaling26.6 million in the prior year [10] - General and administrative expenses also saw a reduction, totaling 5.0 million in Q4 2024 compared to $8.2 million in Q4 2023 [11] Leadership Changes - Dr. Neal Walker has been appointed as the Chief Executive Officer, bringing extensive experience as a co-founder of Aclaris [14] - Hugh Davis has joined as President and Chief Operating Officer, contributing over 35 years of experience in biologics development [14]